Program
Epinephrine
Also written as “epinephrine inhalation aerosol”, “Epinephrine Nasal Spray, 2.5 mg” and “Epinephrine Nasal Spray, 5.25 mg”.
Its studies are mostly in Anaphylaxis · Asthma · Hypersensitivity · Chronic Urticaria · Respiratory Tract Infections, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amphastar Pharmaceuticals | 40 open or running | phase 4since Dec 19, 2019 | Jun 7, 2010 | none ahead |
| Nasus Pharma | 42 open or running | phase 3since Jun 8, 2025 | Dec 1, 2020 | none ahead |
| ARS Pharmaceuticals | 32 open or running | phase 4since Feb 18, 2025 | Jun 9, 2021 | Apr 2027phase 4 · NCT06834165 |
| De Motu Cordis | 20 open or running | phase 1since Nov 9, 2021 | Nov 9, 2021 | none ahead |
| ALK-Abelló | 10 open or running | phase 4since Jun 20, 2013 | Jun 20, 2013 | none ahead |
| Hikma Pharmaceuticals | 11 open or running | phase 2since Aug 18, 2026 | Aug 18, 2026 | May 8, 2027phase 2 · NCT07891780 |
| Smith & Nephew | 10 open or running | phase 2since Apr 5, 2017 | Apr 5, 2017 | none ahead |
Also a collaborator on its studies: medistat-ltd-israel, pharma-medica-research-inc and novotech-australia-pty-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Jun 7, 2010.
- Nov 15, 2011Phase 3 study in AsthmaAmphastar Pharmaceuticals · NCT01476904 · 208 enrolled · United States
- Jun 20, 2013ALK-Abelló's first study: phase 4 study in Handling of Auto-injectorsNew to ALK-AbellóALK-Abelló · NCT01887405 · 91 enrolled · Sweden
- Apr 5, 2017Smith & Nephew's first study: phase 2 study in Healthy VolunteerNew to Smith & NephewSmith & Nephew · NCT03119181 · 40 enrolled · United States
- Dec 19, 2019Phase 4 study in AsthmaAmphastar Pharmaceuticals · NCT04207840 · 28 enrolled · United States
- Dec 1, 2020Nasus Pharma's first study: phase 1 study in AnaphylaxisNew to Nasus PharmaNasus Pharma · NCT04696822 · 12 enrolled · Israel
- Jun 9, 2021ARS Pharmaceuticals's first study: phase 1 study in Respiratory Tract InfectionsNew to ARS PharmaceuticalsARS Pharmaceuticals · NCT04930900 · 15 enrolled · Australia
- Nov 9, 2021De Motu Cordis's first study: phase 1 study in AnaphylaxisNew to De Motu CordisDe Motu Cordis · NCT05152901 · 23 enrolled · Australia
- Aug 22, 2023Phase 1 study in AnaphylaxisDe Motu Cordis · NCT06013150 · 24 enrolled · Australia
- Dec 18, 2023Phase 2 study in AnaphylaxisNasus Pharma · NCT06205134 · 12 enrolled · Israel
- Feb 18, 2025Phase 4 study in HypersensitivityARS Pharmaceuticals · NCT06834165 · 600 planned · United States
- Apr 4, 2025Phase 2 study in Chronic UrticariaARS Pharmaceuticals · NCT06927999 · 42 planned · United States, Germany
- Jun 8, 2025Phase 3 study in Anaphylaxis FoodNasus Pharma · NCT07045701 · 30 planned · Israel
- Nov 6, 2025Phase 2 study in AnaphylaxisNasus Pharma · NCT07228325 · 50 planned · Canada
- Aug 18, 2026Hikma Pharmaceuticals's first study: phase 2 study in Hypersensitivity, ImmediateNew to Hikma PharmaceuticalsHikma Pharmaceuticals · NCT07891780 · 44 planned · United States
Ahead
- Apr 2027Primary completion: phase 4 study in HypersensitivityARS Pharmaceuticals · NCT06834165
- May 8, 2027Primary completion: phase 2 study in Hypersensitivity, ImmediateHikma Pharmaceuticals · NCT07891780
- Jun 2027Primary completion: phase 2 study in Chronic UrticariaARS Pharmaceuticals · NCT06927999
TargetBeta
“Adrenergic receptor agonist; Adrenergic receptor agonist”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07891780Hypersensitivity, Immediate · United States | 2 | Not yet recruiting | Hikma Pharmaceuticals | May 8, 2027 | 44 |
| NCT07228325Anaphylaxis · Canada | 2 | By invitation | Nasus Pharma | Mar 2026 | 50 |
| NCT07045701Anaphylaxis Food · Israel | 3 | By invitation | Nasus Pharma | Jun 12, 2026 | 30 |
| NCT06927999Chronic Urticaria · United States, Germany | 2 | Recruiting | ARS Pharmaceuticals | Jun 2027 | 42 |
| NCT06834165Hypersensitivity · United States | 4 | Recruiting | ARS Pharmaceuticals | Apr 2027 | 600 |
| NCT06205134Anaphylaxis · Israel | 2 | Completed | Nasus Pharma | Feb 2, 2024 | 12 |
| NCT06013150Anaphylaxis · Australia | 1 | Completed | De Motu Cordis | Dec 15, 2023 | 24 |
| NCT05152901Anaphylaxis · Australia | 1 | Completed | De Motu Cordis | Jun 6, 2022 | 23 |
| NCT04930900Respiratory Tract Infections · Australia | 1 | Completed | ARS Pharmaceuticals | Mar 31, 2022 | 15 |
| NCT04696822Anaphylaxis · Israel | 1 | Completed | Nasus Pharma | Sep 28, 2021 | 12 |
| NCT04207840Asthma · United States | 4 | Completed | Amphastar Pharmaceuticals | Dec 20, 2019 | 28 |
| NCT03119181Healthy Volunteer · United States | 2 | Completed | Smith & Nephew | May 11, 2017 | 40 |
| NCT01887405Handling of Auto-injectors · Sweden | 4 | Completed | ALK-Abelló | Sep 2012 | 91 |
| NCT01476904Asthma · United States | 3 | Completed | Amphastar Pharmaceuticals | Apr 2012 | 208 |
| NCT01357642Asthma · United States | 3 | Completed | Amphastar Pharmaceuticals | Nov 2011 | 373 |
| NCT01143051Asthma · United States | 2 | Completed | Amphastar Pharmaceuticals | Jun 2010 | 24 |
How it is read
Names in the registry
- “epinephrine inhalation aerosol”, 4 entries
- “Epinephrine Nasal Spray, 2.5 mg”, 1 entry
- “Epinephrine Nasal Spray, 5.25 mg”, 1 entry
- “0.5 mg epinephrine”, 1 entry
- “1 mg epinephrine”, 1 entry
Codes read as this program: FMXIN002.
Conditions, from the studies’ own filings
- Anaphylaxis, 7 studies
- Asthma, 4 studies
- Hypersensitivity, 2 studies
- Chronic Urticaria, 1 study
- Respiratory Tract Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.